Announcements
- Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
- Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)
- Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur
- Inventiva announces the nomination of Andre Turenne as Director
- Inventiva reports its 2023 full-year results
- Inventiva publie ses résultats annuels 2023
- Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023
- Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
- Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2
- Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 52.48m |
Free float | 42.01m |
P/E (TTM) | -- |
Market cap | 165.83m EUR |
EPS (TTM) | -2.45 EUR |
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼